<DOC>
	<DOCNO>NCT01453387</DOCNO>
	<brief_summary>The main purpose study test experimental drug , MSC2015103B different dose level different treatment schedule , see whether safe tolerate give subject day one day per week 21-day period day three time per week 21-day period . The investigator would also like find MSC2015103B broken body . Additional purpose trial assess side effect MSC2015103B find whether MSC2015103B anti-cancer effect . In addition , investigator would like explore pharmacokinetics .</brief_summary>
	<brief_title>MSC2015103B Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Pathologically confirm solid tumor preferably , exclusively , include pancreatic , thyroid , colorectal , nonsmall cell lung , endometrial , renal , breast , ovarian carcinoma , melanoma locally advanced metastatic , either refractory standard therapy disease effective standard therapy available . 2 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) ≤ 1 . 3 . Has read understands informed consent form willing able give inform consent . Fully understand requirement willing comply trial visit assessment . 4 . Evidence measurable disease trial entry per Response Evaluation Criteria In Solid Tumors ( RECIST ) v1.0 . 5 . Willing provide archival tissue sample molecular analysis . Other inclusion criterion also apply . 1 . Bone marrow impairment evidence hemoglobin &lt; 9.0 g/dL , neutrophil count &lt; 1.5 x 10^9/L , and/or platelet &lt; 100 x 10^9/L . 2 . Renal impairment evidence serum creatinine &gt; 1.5 x ULN ( upper limit normal ) and/or calculate creatinine clearance &lt; 50 mL/min ( CockcroftGault formula ) . 3 . Liver function liver cell integrity abnormality define total bilirubin &gt; 1.5 x ULN , aspartate aminotransferase/alanine aminotransferase ( AST/ALT ) &gt; 2.5 x ULN , subject liver involvement AST/ALT &gt; 5 x ULN . Subjects albumin &lt; 2.5 g/dL also exclude . 4 . History central nervous system ( CNS ) metastases.. 5 . History difficulty swallowing , malabsorption , chronic gastrointestinal disease condition may hamper compliance and/or absorption test product . 6 . Chronic diarrhea ≥ Grade 2 severity 7 . Clinically significant cardiac conduction abnormality . 8 . A left ventricular ejection fraction &lt; 45 % . 9 . A history stroke myocardial infarction within past year . 10 . A history uveitis scleritis . 11 . Retinal pathology beyond normal agerelated process . 12 . Evidence retinal vein occlusion fluorescein angiogram history retinal vein occlusion . Subjects also exclude ophthalmologist find optic disc risk central retinal vein occlusion . 13 . History glaucoma . 14 . Subjects require daily and/or chronic systemic steroid . 15 . Pregnant nursing female . Other exclusion criterion also apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>MEK inhibitor</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Phase I</keyword>
</DOC>